Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Solace Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

Solace Pharmaceuticals Inc. is pursuing identification and development of novel pain compounds based on the scientific work of its pedigreed founders. Launched just a little over a year ago, Solace has already taken its first steps for a Phase IIa proof-of-concept trial in neuropathic pain for its lead compound.
Advertisement
Advertisement

Related Content

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091441

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel